{"Clinical Trial ID": "NCT00717886", "Intervention": ["INTERVENTION 1:", "\u2022 Lymphatic upper extremity mapping for breast cancer patients", "Patients with documented axillary metastases (stage II breast cancer) will undergo a subdermal injection of colloidal sulfur technetium (TCS) into the ipsilateral upper part approximately 3 hours prior to surgery."], "Eligibility": ["Incorporation criteria:", "Females with Stage II invasive breast cancer and axillary metastases documented by central biopsy, clinical examination or aspiration for purposes that are programmed to undergo ADI.", "Women > 21 years", "- Exclusion criteria:", "A previous ipsilateral axillary operation", "Previous ipsilateral axillary radiation", "Previous ipsilateral breast cancer", "Previous ipsilateral breast radiation", "Isosulfan blue colouring Allergy", "ipsilateral lymphedema history of the upper extremity", "Previous history of surgical excision of the upper external quadrant of the ipsilateral breast", "Previous history of neoadjuvant chemotherapy for current breast cancer", "A serious axillary disease at presentation (N2)"], "Results": ["Performance measures:", "Number and prevalence of blue node metastases in the ALND specimen (nails draining the breast).", "[Unspecified]", "Time limit: 2 years", "Results 1:", "Title of the arm/group: Lymphatic upper extremities map for breast cancer patients", "Description of the arm/group: Patients with documented axillary metastases (stage II breast cancer) will undergo a subdermal injection of colloidal sulfur technetium (TCS) into the upper ipsilateral extremity approximately 3 hours prior to surgery.", "Total number of participants analysed: 9", "Type of measurement: Number", "Unit of measurement: participants 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/9 (0.00 per cent)"]}